Description
SYS6090 is an investigational medication currently being studied in clinical trials for advanced colorectal cancer. It is being tested in combination with other treatments, such as bevacizumab (Avastin) and chemotherapy regimens (like those containing 5-FU, irinotecan, oxaliplatin, or regorafenib). The goal of these trials is to evaluate the safety, how well patients tolerate the drug, and whether it has therapeutic benefits for patients with advanced colorectal cancer. The trials are open-label, meaning both the researchers and the patients know which treatment is being given. The trials are multi-center, involving multiple locations, and involve multiple cohorts of patients.
Mechanism of Action
The specific way SYS6090 works (its mechanism of action) is being investigated in clinical trials. It is being studied in combination with other established treatments for colorectal cancer. The trials aim to determine its safety and effectiveness in this setting.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.